Recombinant CTLA-4 (Tremelimumab Biosimilar) 抗体
适用: 人
FACS, in vivo
宿主: 小鼠
Monoclonal
unconjugated
Recombinant Antibody
-
- 抗原
- CTLA-4 (Tremelimumab Biosimilar)
- 抗体类型
- Recombinant Antibody
- 适用
- 人
- 宿主
- 小鼠
- 克隆类型
- 单克隆
- 应用范围
- Flow Cytometry (FACS), In vivo Studies (in vivo)
- 原理
- Tremelimumab Biosimilar, Human CTLA-4 monoclonal antibody
- 特异性
- The in vivo grade tremelimumab biosimilar specifically binds to the human protein receptor CD152 / CTLA4.
- 产品特性
- Recombinant Chimeric IgG2 Monoclonal Antibody.
- 纯化方法
- Protein A affinity column
- 纯度
- > 95% by SDS-PAGE under reducing conditions and HPLC.
- 过滤
- 0.2 μm filtered
- 内毒素水平
- < 1 EU per 1 mg of the protein by the LAL method.
- 免疫原
- The anti-human CTLA-4 monoclonal antibody tremelimumab biosimilar (research grade) was produced in mammalian cells.
- 亚型
- IgG2, kappa
-
- 应用备注
- ELISA, neutralization, in vivo functional assays such as bioanalytical PK and ADA assays, and those in vitro and in vivo assays for studying biological pathways affected by tremelimumab.
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 浓度
- 1 mg/mL
- 缓冲液
- PBS, pH 7.4, no stabilizers or preservatives.
- 储存液
- Without preservative
- 注意事项
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 储存条件
- -20 °C
- 储存方法
- 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
- 有效期
- 12 months
-
- 抗原
- CTLA-4 (Tremelimumab Biosimilar)
- 物质类
- Biosimilar
- 背景
-
What is Tremelimumab biosimilar research grade? Tremelimumab (formerly ticilimumab) is a fully human monoclonal antibody against CTLA-4 / CD152. It is an immune checkpoint blocker. Unlike Ipilimumab (another fully human anti-CTLA-4 / CD152 monoclonal antibody), which is an IgG1 isotype, tremelimumab is an IgG2 isotype.Tremelimumab Biosimilar uses the same protein sequences as the therapeutic antibody tremelimumab.
Tremelimumab aims to stimulate an immune system attack on tumors. Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, there is also an inhibitory mechanism (immune checkpoint) that interrupts this destruction. Tremelimumab turns off this inhibitory mechanism and allows CTLs to continue to destroy the cancer cells. This is immune checkpoint blockade.
Tremelimumab binds to the protein CTLA-4 / CD152, which is expressed on the surface of activated T lymphocytes and inhibits the killing of cancer cells. Tremelimumab blocks the binding of the antigen-presenting cell ligands B7.1 and B7.2 to CTLA-4 / CD152, resulting in inhibition of B7-CTLA-4-mediated downregulation of T-cell activation; subsequently, B7.1 or B7.2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA-4-mediated inhibition.
-
You are here:
